{"originalText": "成骨_细胞数目和作用减少;胰岛素样生长因子合成减少;高血糖及_糖基化终末产物对成骨细胞增殖的抑制;体内活性维生素_D_含_量降低;糖尿病微血管病变导致骨的血管血液供给的减少[18]_._另外,免疫功能异常与糖尿病骨代谢失衡可能存在联系._骨化三醇可以在一定程度上对骨骼脆性变化产生影响,继_而进一步对股骨生物力学产生影响,其原因可能牵涉众多复杂_的机制._研究发现,1_型糖尿病对骨密度及骨骼生物力学的影_响取决于多方面的因素,病程的长短、血糖控制的好坏以及糖_尿病血管并发症(诸如糖尿病肾病等)均参与其中[2]_._流行病_学研究显示,合适的血清维生素_D_水平对于维持骨骼完整性有_着异常重要的作用._维生素_D_在骨的钙磷代谢中起重要作用,_最近的研究显示骨化三醇能对成骨细胞介导的骨矿化起直接_促进作用._然而,资料显示,维生素_D_对糖尿病骨代谢的影响_绝不仅限于此,众多的研究显示,维生素_D_及维生素_D_受体可_能通过异常复杂的机制对糖尿病以及骨代谢产生影响,而最终_出现此种现象[4]_._本实验结果显示:在糖尿病大鼠模型中,骨化三醇干预能_增加骨小梁板厚度和骨小梁体积,改善骨小梁空间结构和骨连_接性,", "entities": [{"label_type": "Disease", "start_pos": 183, "end_pos": 189}, {"label_type": "Disease", "start_pos": 241, "end_pos": 246}, {"label_type": "Drug", "start_pos": 274, "end_pos": 279}, {"label_type": "Drug", "start_pos": 303, "end_pos": 308}, {"label_type": "Drug", "start_pos": 365, "end_pos": 370}, {"label_type": "Drug", "start_pos": 397, "end_pos": 402}, {"label_type": "Anatomy", "start_pos": 337, "end_pos": 341}, {"label_type": "Disease", "start_pos": 103, "end_pos": 106}, {"label_type": "Anatomy", "start_pos": 150, "end_pos": 152}, {"label_type": "Test", "start_pos": 190, "end_pos": 193}, {"label_type": "Test", "start_pos": 220, "end_pos": 222}, {"label_type": "Disease", "start_pos": 229, "end_pos": 238}, {"label_type": "Anatomy", "start_pos": 286, "end_pos": 288}, {"label_type": "Disease", "start_pos": 372, "end_pos": 375}, {"label_type": "Disease", "start_pos": 425, "end_pos": 428}, {"label_type": "Disease", "start_pos": 463, "end_pos": 466}, {"label_type": "Anatomy", "start_pos": 497, "end_pos": 500}, {"label_type": "Drug", "start_pos": 119, "end_pos": 123}, {"label_type": "Drug", "start_pos": 331, "end_pos": 335}, {"label_type": "Drug", "start_pos": 472, "end_pos": 476}, {"label_type": "Anatomy", "start_pos": 194, "end_pos": 196}, {"label_type": "Anatomy", "start_pos": 310, "end_pos": 311}, {"label_type": "Reason", "start_pos": 51, "end_pos": 64}, {"label_type": "Anatomy", "start_pos": 404, "end_pos": 412}, {"label_type": "Reason", "start_pos": 31, "end_pos": 48}, {"label_type": "Reason", "start_pos": 13, "end_pos": 25}, {"label_type": "Reason", "start_pos": 26, "end_pos": 29}, {"label_type": "Reason", "start_pos": 65, "end_pos": 73}, {"label_type": "Reason", "start_pos": 75, "end_pos": 86}, {"label_type": "Test", "start_pos": 132, "end_pos": 136}, {"label_type": "Anatomy", "start_pos": 482, "end_pos": 486}, {"label_type": "Anatomy", "start_pos": 489, "end_pos": 492}]}
{"originalText": "研究_miR-335-5p_对高糖状态_下成骨细胞增殖和凋亡的影响及其分子机制,为糖尿_病性骨病的防治提供理论依据._材料和方法_一、_材料_小鼠_MC3T3-E1_成骨细胞购自上海复祥生物科技_有限公司,_α-MEM_培养基购自_Hyclone_公司,_Opti-_MEM_购自_Gibco_公司(澳洲),RNA_提取试剂盒、逆转_录试剂盒、PCR_试剂盒、引物及_LipofectamineTM_2000_转染试剂盒均购自_Invitrogen_公司,DKK1_鼠源单克隆_抗体购自_Abcam,cysteinyl_aspartate-specific_proteinase-3_(caspase-3),兔源单克隆抗体购自_CST,辣根过氧化物_酶(HRP)标记的_IgG_二抗购自碧云天公司,", "entities": [{"label_type": "Anatomy", "start_pos": 21, "end_pos": 25}, {"label_type": "Anatomy", "start_pos": 83, "end_pos": 87}, {"label_type": "Anatomy", "start_pos": 3, "end_pos": 13}, {"label_type": "Disease", "start_pos": 41, "end_pos": 48}]}
{"originalText": "目前已有_研究证实糖尿病患者长期高血糖可以通过多种途径促进动脉_粥样硬化斑块的形成[4]_._高糖可以导致多种形式的血管内皮_细胞功能失调,_其中内皮细胞凋亡被认为与糖尿病相关的动脉_粥样硬化发生发展有关[5]_._因此,将高糖诱导的血管内皮细胞_的凋亡作为干预的靶点,对预防和延缓糖尿病动脉粥样硬化具_有指导意义._GLP-1_是一种由肠道_L_细胞分泌的重要肠促胰岛素激素,_其通过葡萄糖依赖的方式促进胰岛素分泌、抑制胰升糖素分_泌、延缓胃排空、减少摄食、促进胰岛_β_细胞增殖等作用维持血_糖的稳定,是一种前景广阔的新型降糖药物[6]_._近年研究表明_GLP-1_对心血管系统及内皮细胞功能有着保护作用,但其具体_机制尚未阐明._本研究发现,在高糖状态下加入_1、10_和_100_nmol_/_L_艾塞那肽干预_24_h_后,对内皮细胞活力无明显影响,可_能因为作用时间不足,内皮细胞损伤表现不明显;当干预时间_延长至_48_h_时,可显著提高高糖状态下内皮细胞活力,并呈剂_量依赖性;但干预_72_h_后,艾塞那肽各干预组与高糖对照组相_比细胞活力差异并无统计学意义,", "entities": [{"label_type": "Disease", "start_pos": 29, "end_pos": 36}, {"label_type": "Disease", "start_pos": 89, "end_pos": 96}, {"label_type": "Disease", "start_pos": 144, "end_pos": 150}, {"label_type": "Anatomy", "start_pos": 235, "end_pos": 239}, {"label_type": "Drug", "start_pos": 354, "end_pos": 358}, {"label_type": "Drug", "start_pos": 459, "end_pos": 463}, {"label_type": "Anatomy", "start_pos": 117, "end_pos": 123}, {"label_type": "Anatomy", "start_pos": 159, "end_pos": 164}, {"label_type": "Test", "start_pos": 246, "end_pos": 249}, {"label_type": "Disease", "start_pos": 9, "end_pos": 12}, {"label_type": "Anatomy", "start_pos": 73, "end_pos": 77}, {"label_type": "Disease", "start_pos": 83, "end_pos": 86}, {"label_type": "Disease", "start_pos": 141, "end_pos": 144}, {"label_type": "Anatomy", "start_pos": 169, "end_pos": 176}, {"label_type": "Anatomy", "start_pos": 221, "end_pos": 222}, {"label_type": "Anatomy", "start_pos": 232, "end_pos": 234}, {"label_type": "Anatomy", "start_pos": 287, "end_pos": 290}, {"label_type": "Anatomy", "start_pos": 293, "end_pos": 297}, {"label_type": "Duration", "start_pos": 361, "end_pos": 365}, {"label_type": "Anatomy", "start_pos": 393, "end_pos": 397}, {"label_type": "Duration", "start_pos": 415, "end_pos": 419}, {"label_type": "Duration", "start_pos": 452, "end_pos": 456}, {"label_type": "Anatomy", "start_pos": 58, "end_pos": 65}, {"label_type": "Drug", "start_pos": 280, "end_pos": 285}, {"label_type": "Symptom", "start_pos": 14, "end_pos": 19}, {"label_type": "Anatomy", "start_pos": 369, "end_pos": 373}, {"label_type": "Anatomy", "start_pos": 432, "end_pos": 436}]}
{"originalText": "而_XBP1_与_血糖波动无相关性(P>0._05)._(4)内质网应激相关基因、MCP-1_与血糖波动参数相关._(5)多元_Logistic_逐步回归分析血糖波动是内质网应激相关基因、Ang-2_和_GRACE_的危险因素,LAGE、MPPGE、Bip、IREI、_PERK、ORP150、ATF6_是影响_Ang-2_的危险因素;而_Ang-2、年龄、MAGE、稳态模型评估的胰岛素抵抗指数_(HOMA-IR)、Bip、ATF6_是影响_GRACE_的危险因素._(6)ACS_患者射血分数水平与_MAGE、LAGE_均呈负_相关性,多元线性回归分析显示年龄、HOMA-IR、Ang-2、和_MAGE、Bip、ATF6_可与射血分数建立线性回归关_系._结论_血糖波动使得_Ang-2_升高和导致内质网应激增加,还可能与心脏收缩功能受损有关._增加了患_者的危险度,并影响了_2_型糖尿病合并_ACS_患者的预后._[关键词]___血糖波动;_急性冠状动脉综合征;_糖尿病,", "entities": [{"label_type": "Disease", "start_pos": 391, "end_pos": 397}, {"label_type": "Test", "start_pos": 283, "end_pos": 290}, {"label_type": "Test", "start_pos": 41, "end_pos": 46}, {"label_type": "Test", "start_pos": 9, "end_pos": 11}, {"label_type": "Anatomy", "start_pos": 31, "end_pos": 40}, {"label_type": "Test", "start_pos": 48, "end_pos": 50}, {"label_type": "Anatomy", "start_pos": 84, "end_pos": 93}, {"label_type": "Test", "start_pos": 94, "end_pos": 99}, {"label_type": "Test", "start_pos": 156, "end_pos": 161}, {"label_type": "Reason", "start_pos": 114, "end_pos": 118}, {"label_type": "Reason", "start_pos": 119, "end_pos": 124}, {"label_type": "Reason", "start_pos": 125, "end_pos": 128}, {"label_type": "Reason", "start_pos": 129, "end_pos": 133}, {"label_type": "Reason", "start_pos": 135, "end_pos": 139}, {"label_type": "Reason", "start_pos": 140, "end_pos": 146}, {"label_type": "Reason", "start_pos": 147, "end_pos": 151}, {"label_type": "Disease", "start_pos": 238, "end_pos": 241}, {"label_type": "Test", "start_pos": 291, "end_pos": 296}, {"label_type": "Test", "start_pos": 299, "end_pos": 303}, {"label_type": "Test", "start_pos": 304, "end_pos": 307}, {"label_type": "Test", "start_pos": 308, "end_pos": 312}, {"label_type": "Test", "start_pos": 333, "end_pos": 335}, {"label_type": "Test", "start_pos": 340, "end_pos": 345}, {"label_type": "Disease", "start_pos": 400, "end_pos": 403}, {"label_type": "Test", "start_pos": 419, "end_pos": 421}, {"label_type": "Disease", "start_pos": 222, "end_pos": 227}, {"label_type": "Test", "start_pos": 244, "end_pos": 248}, {"label_type": "Test", "start_pos": 280, "end_pos": 282}, {"label_type": "Test", "start_pos": 315, "end_pos": 319}, {"label_type": "Disease", "start_pos": 425, "end_pos": 434}, {"label_type": "Disease", "start_pos": 436, "end_pos": 439}, {"label_type": "Test", "start_pos": 2, "end_pos": 6}, {"label_type": "Reason", "start_pos": 184, "end_pos": 198}, {"label_type": "Reason", "start_pos": 200, "end_pos": 207}, {"label_type": "Reason", "start_pos": 79, "end_pos": 83}, {"label_type": "Disease", "start_pos": 102, "end_pos": 107}, {"label_type": "Reason", "start_pos": 170, "end_pos": 175}, {"label_type": "Reason", "start_pos": 176, "end_pos": 178}, {"label_type": "Reason", "start_pos": 179, "end_pos": 183}, {"label_type": "Reason", "start_pos": 209, "end_pos": 212}, {"label_type": "Reason", "start_pos": 213, "end_pos": 217}, {"label_type": "Anatomy", "start_pos": 252, "end_pos": 256}, {"label_type": "Anatomy", "start_pos": 257, "end_pos": 261}, {"label_type": "Disease", "start_pos": 363, "end_pos": 371}]}
{"originalText": "观察二者在_1_型糖尿病患者中的变化趋势;实时荧光定量_PCR_检测_Tfh_细胞因子_白细胞介素_21(IL-21)及人_B_细胞淋巴瘤因子_6(Bcl-6)的_mRNA_水平;分析_Tfh_细胞与抗谷氨酸脱羧酶抗_体(GADA)滴度的相关性._结果_(1)与正常对照组相比,新诊断的_1_型糖尿病患者外周血中的_Tfh_细胞_比例显著上升[(0._09_±_0._01_对_0._20_±_0._01)%_,_P<0._01],同时伴有_B_淋巴细胞比例增多[(1._68_±_0._16_对_3._40_±_0._25)%_,_P<0._01];(2)在_1_型糖尿病患者_PBMC_中_Bcl-6_的_mRNA_表达下调_30%_(P<0._01),IL-21_的_mRNA_水平下降_35%_(P<0._05);(3)1_型糖尿病患者_PBMC_中_Tfh_水平与_GADA_水平呈显著正相关(_r=_0._792,_P<0._01)._结论_初发_1_型糖尿病患者外周血_Tfh_比例显著增加,伴随_B_淋巴细胞及_GADA_滴度的_上升,", "entities": [{"label_type": "Disease", "start_pos": 6, "end_pos": 12}, {"label_type": "Disease", "start_pos": 144, "end_pos": 150}, {"label_type": "Disease", "start_pos": 281, "end_pos": 287}, {"label_type": "Disease", "start_pos": 364, "end_pos": 370}, {"label_type": "Disease", "start_pos": 430, "end_pos": 436}, {"label_type": "Anatomy", "start_pos": 290, "end_pos": 294}, {"label_type": "Anatomy", "start_pos": 373, "end_pos": 377}, {"label_type": "Test", "start_pos": 74, "end_pos": 79}, {"label_type": "Test", "start_pos": 100, "end_pos": 110}, {"label_type": "Test", "start_pos": 111, "end_pos": 115}, {"label_type": "Test", "start_pos": 297, "end_pos": 302}, {"label_type": "Test", "start_pos": 329, "end_pos": 334}, {"label_type": "Test", "start_pos": 380, "end_pos": 383}, {"label_type": "Test", "start_pos": 388, "end_pos": 392}, {"label_type": "Test", "start_pos": 456, "end_pos": 462}, {"label_type": "Anatomy", "start_pos": 152, "end_pos": 155}, {"label_type": "Anatomy", "start_pos": 438, "end_pos": 441}, {"label_type": "Anatomy", "start_pos": 35, "end_pos": 38}, {"label_type": "Test_Value", "start_pos": 172, "end_pos": 204}, {"label_type": "Test_Value", "start_pos": 167, "end_pos": 171}, {"label_type": "Test_Value", "start_pos": 229, "end_pos": 231}, {"label_type": "Test_Value", "start_pos": 310, "end_pos": 318}, {"label_type": "Test_Value", "start_pos": 344, "end_pos": 350}, {"label_type": "Test_Value", "start_pos": 448, "end_pos": 452}, {"label_type": "Test_Value", "start_pos": 473, "end_pos": 475}, {"label_type": "Test", "start_pos": 28, "end_pos": 31}, {"label_type": "Test", "start_pos": 44, "end_pos": 52}, {"label_type": "Test", "start_pos": 53, "end_pos": 58}, {"label_type": "Test", "start_pos": 62, "end_pos": 73}, {"label_type": "Anatomy", "start_pos": 93, "end_pos": 96}, {"label_type": "Test", "start_pos": 158, "end_pos": 167}, {"label_type": "Test", "start_pos": 221, "end_pos": 229}, {"label_type": "Test_Value", "start_pos": 233, "end_pos": 246}, {"label_type": "Test_Value", "start_pos": 249, "end_pos": 262}, {"label_type": "Test", "start_pos": 442, "end_pos": 445}, {"label_type": "Test", "start_pos": 464, "end_pos": 471}]}
{"originalText": "评估具体_内容应包括:CCVD_病史、年龄、有无_CCVD_危险因素_(吸烟、脂代谢紊乱、糖代谢紊乱、高血压及家族史、腹_型肥胖)、肾脏损害程度(尿白蛋白排泄率及_GFR_下降_水平)、房颤(可致卒中)、颈动脉狭窄(可致卒中)._评_估普通糖尿病患者_CCVD_病变的原则和方法在_G1_~_4_期患者中也同样适用,但_DKD_患者需使用造影剂时应_充分权衡利弊._G5_期患者存在活动受限,不建议使用_平板运动心电图来评估冠心病,可选用影像学的药物_负荷试验(多巴酚丁胺、潘生丁)_[12]._需注意的是评估_CCVD_的常用实验室指标(脑钠肽、肌钙蛋白等)和无_创性检查(心电图负荷试验、超声心动图、核素显像_等)在_DKD_患者中应用存在一定的局限性[12]._2._营养状态:由于厌食和消化功能紊乱,蛋白质、_能量摄入不足以及内分泌代谢障碍,使_DKD_患者营养_不良的发生率较高,", "entities": [{"label_type": "Test", "start_pos": 82, "end_pos": 85}, {"label_type": "Test", "start_pos": 206, "end_pos": 209}, {"label_type": "Disease", "start_pos": 11, "end_pos": 15}, {"label_type": "Disease", "start_pos": 25, "end_pos": 29}, {"label_type": "Disease", "start_pos": 126, "end_pos": 130}, {"label_type": "Disease", "start_pos": 256, "end_pos": 260}, {"label_type": "Disease", "start_pos": 212, "end_pos": 215}, {"label_type": "Disease", "start_pos": 160, "end_pos": 163}, {"label_type": "Disease", "start_pos": 311, "end_pos": 314}, {"label_type": "Disease", "start_pos": 377, "end_pos": 380}, {"label_type": "Disease", "start_pos": 93, "end_pos": 95}, {"label_type": "Disease", "start_pos": 98, "end_pos": 100}, {"label_type": "Disease", "start_pos": 102, "end_pos": 107}, {"label_type": "Disease", "start_pos": 110, "end_pos": 112}, {"label_type": "Disease", "start_pos": 120, "end_pos": 123}, {"label_type": "Drug", "start_pos": 231, "end_pos": 236}, {"label_type": "Test", "start_pos": 296, "end_pos": 301}, {"label_type": "Test", "start_pos": 302, "end_pos": 306}, {"label_type": "Disease", "start_pos": 67, "end_pos": 70}, {"label_type": "Test", "start_pos": 223, "end_pos": 230}, {"label_type": "Disease", "start_pos": 344, "end_pos": 346}, {"label_type": "Disease", "start_pos": 347, "end_pos": 353}, {"label_type": "Disease", "start_pos": 367, "end_pos": 374}, {"label_type": "Disease", "start_pos": 383, "end_pos": 388}, {"label_type": "Reason", "start_pos": 36, "end_pos": 38}, {"label_type": "Level", "start_pos": 141, "end_pos": 149}, {"label_type": "Level", "start_pos": 183, "end_pos": 187}, {"label_type": "Test", "start_pos": 73, "end_pos": 80}, {"label_type": "Reason", "start_pos": 39, "end_pos": 44}, {"label_type": "Reason", "start_pos": 45, "end_pos": 50}, {"label_type": "Reason", "start_pos": 51, "end_pos": 58}, {"label_type": "Reason", "start_pos": 59, "end_pos": 64}, {"label_type": "Drug", "start_pos": 237, "end_pos": 240}, {"label_type": "Test", "start_pos": 270, "end_pos": 273}, {"label_type": "Test", "start_pos": 274, "end_pos": 278}, {"label_type": "Test", "start_pos": 288, "end_pos": 295}]}
{"originalText": "表_2)._三、_相关及回归分析_Pearson_直线相关分析表明:CIMT_与_TLR4、IL-6、_hs-CRP、MCP-1、空腹血糖、HBA1C、HOMA-IR_及年龄呈_正相关(_r=_0._540、0._244、0._271、0._329、0._381、0._490、_0._471、0._410,均_P<0._05),与_HDL-C_呈负相关(_r_=_-0._323,P_<_0._05)._TLR4_与_CIMT、HOMA-IR、_IL-6、_hs-CRP_和_MCP-1、空腹血糖和_HBA1C_呈正相关_(_r_=_0._540、0._428、0._214、0._242、0._385、0._445、0._367,均_P<0._05),与_HDL-C_呈负相关(_r=_-0._384,P<0._05)._以_CIMT_为应变量,TLR4、IL-6、hs-CRP、MCP-1、空_腹血糖、HBA1C、HOMA-IR、血脂及年龄等作为自变量_进行多元线性逐步回归分析,在调整了性别、体重指_数、吸烟及病程等因素后,结果显示_TLR4(R2_=_0._292,", "entities": [{"label_type": "Test", "start_pos": 70, "end_pos": 75}, {"label_type": "Test", "start_pos": 251, "end_pos": 256}, {"label_type": "Test", "start_pos": 404, "end_pos": 409}, {"label_type": "Test", "start_pos": 167, "end_pos": 172}, {"label_type": "Test", "start_pos": 330, "end_pos": 335}, {"label_type": "Test", "start_pos": 65, "end_pos": 69}, {"label_type": "Test", "start_pos": 245, "end_pos": 249}, {"label_type": "Test", "start_pos": 398, "end_pos": 403}, {"label_type": "Test", "start_pos": 76, "end_pos": 83}, {"label_type": "Test", "start_pos": 215, "end_pos": 222}, {"label_type": "Test", "start_pos": 410, "end_pos": 417}, {"label_type": "Test", "start_pos": 450, "end_pos": 452}, {"label_type": "Test", "start_pos": 59, "end_pos": 64}, {"label_type": "Test", "start_pos": 239, "end_pos": 244}, {"label_type": "Test", "start_pos": 392, "end_pos": 397}, {"label_type": "Test", "start_pos": 34, "end_pos": 38}, {"label_type": "Test", "start_pos": 46, "end_pos": 50}, {"label_type": "Test", "start_pos": 52, "end_pos": 58}, {"label_type": "Test", "start_pos": 210, "end_pos": 214}, {"label_type": "Test", "start_pos": 224, "end_pos": 228}, {"label_type": "Test", "start_pos": 230, "end_pos": 236}, {"label_type": "Test", "start_pos": 365, "end_pos": 369}, {"label_type": "Test", "start_pos": 380, "end_pos": 384}, {"label_type": "Test", "start_pos": 385, "end_pos": 391}, {"label_type": "Test", "start_pos": 418, "end_pos": 420}, {"label_type": "Test", "start_pos": 421, "end_pos": 423}, {"label_type": "Test", "start_pos": 41, "end_pos": 45}, {"label_type": "Test", "start_pos": 203, "end_pos": 207}, {"label_type": "Test", "start_pos": 375, "end_pos": 379}, {"label_type": "Reason", "start_pos": 471, "end_pos": 475}]}
{"originalText": "_but_attenuated_significantly_in_the_presence_of_50_ng_/_ml_LXA4_._Conclusion_LXA4_may_inhibit_the_expressions_of_inflammatory_related_factors_induced_by_UA_via_reducing_p38_MAPK_and_NF-κB_/_p65_phosphorylation_and_play_a_role_in_anti-inflammation._[Key_words]__Lipoxin_A4;_Uric_acid;_Human_umbilical_vein_endothelial_cells;_p38_mitogen-activated_protein_kinase;_NF-κB_/_p65_(Chin_J_Endocrinol_Metab,_2015,_31:_800-805)_近年来,随着人类生活水平提高和膳食结构改变,_高尿酸血症的发病率在世界范围内呈上升趋势,严重_威胁人类的健康._大量研究证实高尿酸血症不仅是痛_风的生化基础,", "entities": [{"label_type": "Test", "start_pos": 154, "end_pos": 156}, {"label_type": "Disease", "start_pos": 490, "end_pos": 493}, {"label_type": "Disease", "start_pos": 443, "end_pos": 448}, {"label_type": "Reason", "start_pos": 482, "end_pos": 487}]}
{"originalText": "提高棕色组织产热为防治肥胖研究奠定_了理论基础._运动是防治肥胖的有效方式._2012_年初_Bostr觟m_等[10]研究发现运动诱导骨骼肌表达过氧化物酶体增_殖物激活受体_γ_辅助激活因子_α(PGC-1α),后者可促_进3型纤连蛋白结构域_5_(_FNDC5)_的表达,随后_FNDC5_在体内被剪切转变为一种新的形式_Irisin._Irisin_从骨骼肌合成分泌后,通过血液循环作用于_WAT,使_WAT_内_UCP-1_表达增加,从而使_WAT_转变_为具有分解代谢脂肪特征的_BAT._因此,Irisin_将成为_肥胖防治研究的新靶点._本研究旨在探讨人体血_Irisin_水平与超重_/肥胖及相关代谢参数的关系._对象和方法_一、_对象_175_名(男性_72_名,女性_103_名)40_~_60_岁身体健_康的调查对象均来自_2012_年_12_月至_2013_年_9_月于_上海市奉贤区展开以社区为基础的健康调查._所有受_试者依次进行身高、体重测定,根据世界卫生组织诊断_标准,体重指数(BMI)≥25_kg_/_m2,即可诊断超重_/肥_胖,", "entities": [{"label_type": "Test", "start_pos": 451, "end_pos": 455}, {"label_type": "Test", "start_pos": 456, "end_pos": 459}, {"label_type": "Test", "start_pos": 429, "end_pos": 431}, {"label_type": "Test", "start_pos": 432, "end_pos": 434}, {"label_type": "Anatomy", "start_pos": 245, "end_pos": 248}, {"label_type": "Anatomy", "start_pos": 198, "end_pos": 201}, {"label_type": "Anatomy", "start_pos": 204, "end_pos": 207}, {"label_type": "Anatomy", "start_pos": 225, "end_pos": 228}, {"label_type": "Test", "start_pos": 253, "end_pos": 259}, {"label_type": "Test", "start_pos": 287, "end_pos": 293}, {"label_type": "Anatomy", "start_pos": 2, "end_pos": 6}, {"label_type": "Disease", "start_pos": 11, "end_pos": 13}, {"label_type": "Disease", "start_pos": 30, "end_pos": 32}, {"label_type": "Anatomy", "start_pos": 68, "end_pos": 71}, {"label_type": "Anatomy", "start_pos": 179, "end_pos": 182}, {"label_type": "Disease", "start_pos": 264, "end_pos": 266}, {"label_type": "Disease", "start_pos": 297, "end_pos": 303}, {"label_type": "Disease", "start_pos": 476, "end_pos": 483}, {"label_type": "Anatomy", "start_pos": 239, "end_pos": 241}, {"label_type": "Test", "start_pos": 306, "end_pos": 310}, {"label_type": "Anatomy", "start_pos": 113, "end_pos": 124}, {"label_type": "Anatomy", "start_pos": 141, "end_pos": 146}, {"label_type": "Test_Value", "start_pos": 461, "end_pos": 471}, {"label_type": "Test", "start_pos": 163, "end_pos": 169}, {"label_type": "Test", "start_pos": 171, "end_pos": 177}, {"label_type": "Test", "start_pos": 210, "end_pos": 215}, {"label_type": "Anatomy", "start_pos": 74, "end_pos": 98}]}
{"originalText": "探讨_TSH_是否参与胰岛素抵抗的发生及可能机制._一、_材料和方法_1._材料:3T3-L1_前脂肪细胞株、DMEM_高糖培养基购于南_京_KeyGNE_公司;3-异丁基-1-甲基黄嘌呤(_IBMX)、胰岛素、地_塞米松、油红_O、牛_TSH_购于美国_Sigma_公司;TNF-α_拮抗剂_WP9QY_购于美国_Santa_cruz_公司;LipofectamineTM_2000_购于美_国_Invitrogen_公司;高纯质粒抽提试剂盒购于北京_TIANGEN_公_司;小鼠_TNF-α_酶联免疫检测试剂盒购于美国_R&D_systems_公_司;小鼠单克隆_IRS-1_抗体、IRS-1_酪氨酸磷酸化抗体———抗_Phospho-cdc2(Tyr15)兔单克隆抗体、Protein_A+G_琼脂糖购于碧_云天生物技术研究所._β-tubulin_抗体购于天津三箭生物技术_公司;辣根过氧化物酶标记的二抗均购于北京中山金桥生物技_术有限公司;增强化学发光(ECL)试剂盒购于北京全式金生物_技术有限公司._2._方法:(1)3T3-L1_前脂肪细胞培养和诱导分化:将细胞_以_1._5×104_/_cm2细胞密度接", "entities": [{"label_type": "Test", "start_pos": 3, "end_pos": 6}, {"label_type": "Drug", "start_pos": 102, "end_pos": 105}, {"label_type": "Drug", "start_pos": 106, "end_pos": 111}, {"label_type": "Anatomy", "start_pos": 41, "end_pos": 53}, {"label_type": "Drug", "start_pos": 81, "end_pos": 101}, {"label_type": "Anatomy", "start_pos": 466, "end_pos": 478}, {"label_type": "Test", "start_pos": 119, "end_pos": 122}, {"label_type": "Drug", "start_pos": 137, "end_pos": 146}, {"label_type": "Drug", "start_pos": 147, "end_pos": 152}, {"label_type": "Test", "start_pos": 242, "end_pos": 247}, {"label_type": "Anatomy", "start_pos": 284, "end_pos": 289}, {"label_type": "Anatomy", "start_pos": 293, "end_pos": 298}, {"label_type": "Reason", "start_pos": 11, "end_pos": 16}]}
